- Home
- DCI vs RGEN Comparison
DCI vs RGEN Comparison
Compare DCI & RGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DCI
- RGEN
- Stock Information
- Founded
- DCI 1915
- RGEN 1981
- Country
- DCI United States
- RGEN United States
- Employees
- DCI N/A
- RGEN N/A
- Industry
- DCI Pollution Control Equipment
- RGEN Medical/Dental Instruments
- Sector
- DCI Industrials
- RGEN Health Care
- Exchange
- DCI Nasdaq
- RGEN Nasdaq
- Market Cap
- DCI 8.4B
- RGEN 8.2B
- IPO Year
- DCI 1987
- RGEN N/A
- Fundamental
- Price
- DCI $71.30
- RGEN $140.00
- Analyst Decision
- DCI Hold
- RGEN Buy
- Analyst Count
- DCI 4
- RGEN 10
- Target Price
- DCI $69.67
- RGEN $188.38
- AVG Volume (30 Days)
- DCI 451.9K
- RGEN 783.2K
- Earning Date
- DCI 08-28-2024
- RGEN 10-29-2024
- Dividend Yield
- DCI 1.52%
- RGEN N/A
- EPS Growth
- DCI 16.55
- RGEN N/A
- EPS
- DCI 3.38
- RGEN N/A
- Revenue
- DCI $3,586,300,000.00
- RGEN $602,354,000.00
- Revenue This Year
- DCI $5.29
- RGEN $0.08
- Revenue Next Year
- DCI $5.64
- RGEN $12.97
- P/E Ratio
- DCI $21.08
- RGEN N/A
- Revenue Growth
- DCI 4.53
- RGEN N/A
- 52 Week Low
- DCI $57.05
- RGEN $110.45
- 52 Week High
- DCI $78.03
- RGEN $211.13
- Technical
- Relative Strength Index (RSI)
- DCI 48.00
- RGEN 41.03
- Support Level
- DCI $68.94
- RGEN $138.80
- Resistance Level
- DCI $70.70
- RGEN $150.72
- Average True Range (ATR)
- DCI 1.22
- RGEN 5.04
- MACD
- DCI -0.09
- RGEN -1.06
- Stochastic Oscillator
- DCI 39.48
- RGEN 8.50
About DCI Donaldson Company Inc.
Donaldson is a leading manufacturer of filtration systems and replacement parts (including air filtration systems, liquid filtration systems, and dust, fume, and mist collectors). The company serves a diverse range of end markets, including construction, mining, agriculture, truck, and industrial. Its business is organized into three segments: mobile solutions, industrial solutions, and life sciences. Donaldson generated approximately $3.6 billion in revenue and $544 million in operating income in its fiscal 2024.
About RGEN Repligen Corporation
Repligen Corp is a global life sciences company. It develops and commercializes innovative bioprocessing technologies and systems that increase efficiencies and flexibility in the process of manufacturing biological drugs. The company's customers include life science companies, global biopharmaceutical companies, and contract manufacturers worldwide. Repligen markets its products globally through a direct commercial organization in the U.S., Europe, and Asia, as well as through strategic partners in select markets. The majority of the company's revenue is generated in North America.